Association of Sex with Survival and Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Single-Center Experience in Türkiye

01 April 2025 : Clinical Research

Melike Yüksel Yavuz

^{ABCDEF 1*}, Filiz Karapinar

^{ABDE 2}, Ceyda Anar

^{DEF 3}, Mehdi Ok

^{CD 2}, Sema Ertürk

^{CD 4}, Mine Gayaf

^{DEF 2}, Fatma Demirci Üçsular

^{DEF 2}, Gülru Polat

^{DEF 2}

DOI: 10.12659/MSM.947817

Med Sci Monit 2025; 31:e947817

Authors information Article notes Copyright and License information

Introduction Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 3 Laboratory, PDL-1 level, histology and side effects data of patients according to sex*.

		Sex				P
		Men		Women		P
Albumin	Median (IQR)	41.9 (38.8–43.8)		40.6 (39.6–42.8)		0.098
LDH	Median (IQR)	198.5 (169.5–236.2)		194.5 (145.2–302.2)		0.663

PDL-1 level	Unknown	39	44.8	4	33.3	0.552
	Negative	28	32.2	6	50.0
	Weak positive	19	21.8	2	16.7
	Strong positive	1	1.1	0	0.0
Histology	Adenocarcinoma	54	61.4	9	75.0	0.557
	SCC	30	34.1	3	25.0
	Other	4	4.5	0	0.0
Tiredness	No	48	54.5	7	58.3	0.804
Tiredness	Yes	40	44.5	5	41.7	0.804
Pneumonitis	No	84	95.4	10	83.3	0.097
Pneumonitis	Yes	4	4.6	2	16.7	0.097
Pleural effusion	No	87	98.8	11	91.6
Pleural effusion	Yes	1	1.2	1	8.4
Hypothyroidism	No	85	96.5	9	75.0
Hypothyroidism	Yes	3	3.5	3	25.0
Rash	No	68	77.2	2	16.6
Rash	Yes	20	22.8	10	83.4
Hyperthyroidism	No	86	97.7	12	100.0	0.597
Hyperthyroidism	Yes	2	2.3	0	0.0	0.597
LDH – lactate dehydrogenase; PDL-1 – programmed cell death ligand-1. ^* Chi-square analysis was used to compare categorical data, and the Mann-Whitney U test was used to compare continuous data.

Back to the Article